Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Voyageur Pharmaceuticals ( (TSE:VM) ) just unveiled an update.
Voyageur Pharmaceuticals has engaged VAST Resource Solutions to advance its Frances Creek Barite Project by preparing a Bulk Sample Permit Application. This engagement is a significant step towards a full-scale feasibility study anticipated in 2026, positioning Voyageur to build a secure, vertically integrated supply chain for pharmaceutical-grade barium sulfate in North America. The Frances Creek deposit is seen as a strategic asset that could reduce dependency on foreign-sourced materials, aligning with Voyageur’s vision of ‘From the Earth to the Bottle’ to ensure quality and cost efficiency in the radiology contrast media drug market.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on developing barium and iodine Active Pharmaceutical Ingredients (API) for high-performance imaging contrast agents. The company aims to become a key player in the contrast media market by vertically integrating the production of barium and iodine, and is also pursuing the development of new endo fullerene drugs. Voyageur plans to generate sales through partnerships with established third-party GMP pharmaceutical manufacturers in Canada, with a long-term goal of becoming a high-margin domestic manufacturer of radiology drugs.
YTD Price Performance: 94.44%
Average Trading Volume: 208,080
Technical Sentiment Signal: Buy
Current Market Cap: C$29.45M
Learn more about VM stock on TipRanks’ Stock Analysis page.